Community Bank of Raymore Increases Position in Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Community Bank of Raymore increased its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,005 shares of the biopharmaceutical company’s stock after buying an additional 200 shares during the quarter. Community Bank of Raymore’s holdings in Bristol-Myers Squibb were worth $514,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nuveen Asset Management LLC lifted its position in Bristol-Myers Squibb by 14,860.1% during the second quarter. Nuveen Asset Management LLC now owns 9,395,120 shares of the biopharmaceutical company’s stock valued at $426,069,000 after purchasing an additional 9,332,319 shares during the period. BlackRock Inc. lifted its position in Bristol-Myers Squibb by 6.7% during the second quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock valued at $5,206,108,000 after purchasing an additional 7,178,698 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Bristol-Myers Squibb by 42.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 12,749,545 shares of the biopharmaceutical company’s stock valued at $578,192,000 after purchasing an additional 3,816,247 shares during the period. Eaton Vance Management lifted its position in Bristol-Myers Squibb by 108.3% during the second quarter. Eaton Vance Management now owns 5,195,648 shares of the biopharmaceutical company’s stock valued at $235,623,000 after purchasing an additional 2,701,008 shares during the period. Finally, Prudential PLC lifted its position in Bristol-Myers Squibb by 438.6% during the second quarter. Prudential PLC now owns 2,907,501 shares of the biopharmaceutical company’s stock valued at $130,846,000 after purchasing an additional 2,367,644 shares during the period. 83.02% of the stock is currently owned by hedge funds and other institutional investors.

In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the completion of the transaction, the senior vice president now owns 74,471 shares in the company, valued at $4,219,526.86. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Louis S. Schmukler sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the transaction, the insider now owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.

Shares of Bristol-Myers Squibb stock opened at $66.58 on Thursday. The firm has a 50-day simple moving average of $62.52 and a two-hundred day simple moving average of $53.03. The company has a market cap of $108.25 billion, a P/E ratio of 16.73, a price-to-earnings-growth ratio of 0.85 and a beta of 0.73. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $67.09. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.11. The business had revenue of $6.01 billion during the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.09 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb Co will post 4.47 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a $0.45 dividend. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.70%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. Bristol-Myers Squibb’s dividend payout ratio is 45.23%.

BMY has been the subject of a number of research reports. Argus upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 target price for the company in a research report on Friday, December 13th. Morgan Stanley initiated coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 22nd. They set an “equal weight” rating and a $60.00 target price for the company. Wolfe Research set a $66.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, November 1st. Bank of America initiated coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, October 16th. They set a “buy” rating and a $60.00 target price for the company. Finally, TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Buy” and a consensus price target of $61.69.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: Buy Rating

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.